Webcast (1 of 4):
KT 101: Knowledge Translation Initiatives at CIHR
About the Webcast:
Dr. Alisa Schaefer provides an overview of the Knowledge to Action Cycle and several funding opportunities that have been implemented to advance knowledge translation in order to lead to improved health through evidence-based practice and care. Dr. Neil Cashman describes his efforts using the KT strategy of “commercialization” to advance his work in neurodegeneration. (Originally aired Aug. 20, 2014.)
View the Archive
-
This webcast can be viewed via YouTube: http://youtu.be/matYUyZxywg
- To increase volume, turn up the volume on your computer and use the volume bar on bottom left side of the YouTube video window.
- Captioning is available by selecting the "CC" option on the bottom right side of the video window. Click on "Options" to change the font, size, and color of the captions.
- Additional tools on the bottom right side: “Settings" increase the video quality; "Theater mode" (default)/"Full screen.”
- Edited Transcript of the presentation (MS Word™ 80kb DOCX)
- Presentation Materials:
- Download a copy of the slides used during the session: webcast_082014.pdf
- Text version of PowerPoint™ presentation: webcast_082014.docx
- Please fill out the brief evaluation after viewing the webcast.
About the Presenters:
Alisa Schaefer, Ph.D., is Senior Advisor for Knowledge Translation at the Canadian Institutes of Health Research. In this capacity, she is focused on analytical measures of knowledge translation and the support of commercialization funding opportunities. Dr. Schaefer received her Ph.D. in 2007 from Uniformed Services University of the Health Sciences. She was an American Association for the Advancement of Science Policy Fellow at the National Institutes of Health, where she worked on legislative, policy, commercialization and global health matters.
Dr. Neil Cashman is a Professor of Medicine at the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases. He has authored over 300 publications, has an H-index of 50, and has more than 10,000 career citations. He was cited by CIHR for the “Medical Milestone” of identifying a prion-specific epitope in 2003. He was Scientific Director/CEO of PrioNet Canada one of the Network of Centres of Excellence, and is Founder and Chief Scientific Officer of Amorfix Life Sciences since 2005.